Animal health's safety from patent cliff is an investment stimulator
The long product lifecycles in the animal health sector are a key characteristic for attracting R&D investment, according to George Gunn.
Pet tech start-up Scollar chooses KC as headquarters, ponders partnerships and expansion
Founded in 2015, US-based pet technology start-up Scollar markets a cloud-enabled smart collar that is designed to address every aspect of animal care in an "all-in-one" solution for pets. Previously based in Silicon Valley, it will now be moving its headquarters to Kansas City. Animal Pharm analyst Daniel Willis spoke to Scollar co-founder and chief executive Lisa Tamayo to find out more.
CombiGene makes bid for pet gene therapies through synergistic Panion deal
Shareholders of Panion Animal Health have agreed to accept an acquisition offer from the company's former parent CombiGene.
Bayer signs monoclonal antibody development deal for pets with adivo
Bayer Animal Health is the latest firm to strengthen its abilities in the growing veterinary antibody therapy space by signing a global collaboration agreement with German start-up adivo.
Next-generation sequencing at the core of MicroGen Vet's diagnostic offering
US firm MicroGen Vet hopes to bring its diagnostics expertise from human healthcare to bring next-generation sequencing (NGS) to animal health.
Boehringer bags minority stake in swine tech business SoundTalks
Boehringer Ingelheim Animal Health has acquired a minority stake in Belgian technology specialist SoundTalks.
Latest Articles
Recent Tweets from Animal Pharm
Tweets by animalpharm
Commercial
Black swans and battlegrounds: McKinsey expert predicts 'new rules' for animal health's future
A senior partner at management consultancy firm McKinsey believes the animal health sector is "a tale of two cities".
Latest From
USDA to grant exclusive license to Huvepharma for ASF vaccine work
Huvepharma is the latest company to join the race to develop the first viable vaccine against African swine fever (ASF).
Elanco supports Cultivian Sandbox's third venture fund
Cultivian Sandbox Ventures has closed its third venture capital fund at $135 million, with backing from long-term supporter Elanco.
ELIAS cancer immunotherapy answers the 'three big questions' for investors
ELIAS Animal Health believes its diligence in gathering trial data for its personalized canine cancer drug will help it secure funding and create treatment confidence among veterinarians.
Parnell turnaround continues with 39% full-year sales hike
Australian company Parnell Pharmaceuticals has reported 39% growth for 2018, as turnover came to Aus$26.5 million ($19 million).
Livestock industry partners release national M bovis eradication plan
Three partners working to eliminate Mycoplasma bovis (M bovis) in New Zealand have launched their 2019 national eradication plan.
PBD Biotech appoints new leader, as chief executive retires
UK start-up PBD Biotech has made Mark Hammond its new chief executive.
Top Interviews & Analysis
Clint Lewis outlines plan to make Abaxis into broader diagnostics player
Zoetis has gone from a couple of exploratory acquisitions to being a key market player in veterinary diagnostics, according to executive vice president Clint Lewis. Animal Pharm editor Joseph Harvey got the lowdown from Mr Lewis on this relatively new but burgeoning area for Zoetis, while analyst Sian Lazell listened to his opening keynote speech at the recent Animal Health Investment Europe conference in London.
Products
Bayer stokes further Seresto growth with launch in China
Bayer Animal Health will stimulate even further growth from its Seresto flea and tick collar after introducing the product to the Chinese market.
Latest From
USDA to grant exclusive license to Huvepharma for ASF vaccine work
Huvepharma is the latest company to join the race to develop the first viable vaccine against African swine fever (ASF).
Elanco supports Cultivian Sandbox's third venture fund
Cultivian Sandbox Ventures has closed its third venture capital fund at $135 million, with backing from long-term supporter Elanco.
ELIAS cancer immunotherapy answers the 'three big questions' for investors
ELIAS Animal Health believes its diligence in gathering trial data for its personalized canine cancer drug will help it secure funding and create treatment confidence among veterinarians.
Parnell turnaround continues with 39% full-year sales hike
Australian company Parnell Pharmaceuticals has reported 39% growth for 2018, as turnover came to Aus$26.5 million ($19 million).
Livestock industry partners release national M bovis eradication plan
Three partners working to eliminate Mycoplasma bovis (M bovis) in New Zealand have launched their 2019 national eradication plan.
PBD Biotech appoints new leader, as chief executive retires
UK start-up PBD Biotech has made Mark Hammond its new chief executive.
Data Pharm
Bayer sees growth in fourth quarter, not enough to save full year
Bayer Animal Health has witnessed a 2.5% improvement in revenues during the fourth quarter of 2018.
Elanco continues turnaround with pet preventatives boosting Q4
Elanco's fourth-quarter sales grew by 6%, with the firm's companion animal disease prevention products supporting this performance.
Sectors
Pet technology experts underline barriers to success in a crowded space
At the recent Animal Health Investment Europe forum in London, Animal Pharm editor Joseph Harvey led a panel discussion on digital personalization in pet care. He spoke to three companies in this area – Fitbark, Antelliq and Felcana. Below is an excerpt of the panel discussion.
Latest From
USDA to grant exclusive license to Huvepharma for ASF vaccine work
Huvepharma is the latest company to join the race to develop the first viable vaccine against African swine fever (ASF).
Elanco supports Cultivian Sandbox's third venture fund
Cultivian Sandbox Ventures has closed its third venture capital fund at $135 million, with backing from long-term supporter Elanco.
ELIAS cancer immunotherapy answers the 'three big questions' for investors
ELIAS Animal Health believes its diligence in gathering trial data for its personalized canine cancer drug will help it secure funding and create treatment confidence among veterinarians.
Parnell turnaround continues with 39% full-year sales hike
Australian company Parnell Pharmaceuticals has reported 39% growth for 2018, as turnover came to Aus$26.5 million ($19 million).
Livestock industry partners release national M bovis eradication plan
Three partners working to eliminate Mycoplasma bovis (M bovis) in New Zealand have launched their 2019 national eradication plan.
PBD Biotech appoints new leader, as chief executive retires
UK start-up PBD Biotech has made Mark Hammond its new chief executive.
Latest From
USDA to grant exclusive license to Huvepharma for ASF vaccine work
Huvepharma is the latest company to join the race to develop the first viable vaccine against African swine fever (ASF).
Elanco supports Cultivian Sandbox's third venture fund
Cultivian Sandbox Ventures has closed its third venture capital fund at $135 million, with backing from long-term supporter Elanco.
ELIAS cancer immunotherapy answers the 'three big questions' for investors
ELIAS Animal Health believes its diligence in gathering trial data for its personalized canine cancer drug will help it secure funding and create treatment confidence among veterinarians.
Parnell turnaround continues with 39% full-year sales hike
Australian company Parnell Pharmaceuticals has reported 39% growth for 2018, as turnover came to Aus$26.5 million ($19 million).
Livestock industry partners release national M bovis eradication plan
Three partners working to eliminate Mycoplasma bovis (M bovis) in New Zealand have launched their 2019 national eradication plan.
PBD Biotech appoints new leader, as chief executive retires
UK start-up PBD Biotech has made Mark Hammond its new chief executive.
Policy & Regulation
Experts err on the side of caution over forthcoming European regulations
A joint conference hosted by AnimalhealthEurope and Klifovet in Munich gave a detailed overview of the new European regulation on veterinary medicines and the impact it will have on product development and lifecycle management. Animal Pharm editor Joseph Harvey was in attendance to gauge the reaction to the proposed new rules.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.